Share this article
Share this article
PALM BEACH, Fla., Feb. 23, 2021 /PRNewswire/ In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue to do so for several years to come. T-cell therapy includes using genetically engineered T-cells to produce an artificial T-cell receptor for applications in immunotherapy. Growing prevalence of cancer across the world and increase in cancer research & development drive the market. According to the WHO, the number of global cancer deaths is projected to increase by 45% between 2008 and 2030. It is also estimated that by 2030, approximately 10 to 11 million cases of cancers would be diagnosed each year in low- and middle-income countries. The increase in investment in adoptive T-cell transfer approaches of disease treatment drives and the increasing number of clinical trials the market. Furthermore, technological advancements i
Palm Beach, FL –February 23, 2021 – In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue to do so for several years to come. T-cell therapy includes using genetically engineered T-cells to produce an artificial T-cell receptor for applications in immunotherapy. Growing prevalence of cancer across the world and increase in cancer research & development drive the market. According to the WHO, the number of global cancer deaths is projected to increase by 45% between 2008 and 2030. It is also estimated that by 2030, approximately 10 to 11 million cases of cancers would be diagnosed each year in low- and middle-income countries. The increase in investment in adoptive T-cell transfer approaches of disease treatment drives and the increasing number of clinical trials the market. Furthermore, technological advancements in manufacturing processes and developments in CAR